Revakinagene taroretcel

Revakinagene taroretcel
Clinical data
Trade namesEncelto
Other namesNTC-201-6A, revakinagene taroretcel-lwey
AHFS/Drugs.comMonograph
MedlinePlusa625063
License data
Routes of
administration
Intravitreal implantation
ATC code
  • None
Legal status
Legal status
Identifiers
UNII
KEGG

Revakinagene taroretcel, sold under the brand name Encelto, is an allogeneic encapsulated cell-based gene therapy used for the treatment of macular telangiectasia type 2. Revakinagene taroretcel is administered into the recipient's eye during a single surgical procedure.

Revakinagene taroretcel works by expressing recombinant human ciliary neurotrophic factor, which is a factor that may promote the survival and maintenance of the macular photoreceptors.

Revakinagene taroretcel was approved for medical use in the United States in March 2025.

Medical uses

Revakinagene taroretcel is indicated for the treatment of adults with idiopathic macular telangiectasia type 2.

Macular telangiectasia type 2 is a rare progressive disease of the macula (portion of the eye that process sharp central vision), leading to degeneration of the photoreceptors which are specialized light-detecting cells in the back of the eye.

Society and culture

Revakinagene taroretcel was approved for medical use in the United States in March 2025.

Names

Revakinagene taroretcel is the international nonproprietary name and the United States Adopted Name.